The purpose of this research work was to evaluate the contribution of formulation variables on release properties of matrix type ocular films containing chloramphenicol as a model drug. This study investigated the use of cellulose acetate and cellulose acetate butyrate as film-forming agents in development of ocular films. Formulation variables were concentration of polymer and plasticizer. Prepared films were evaluated for thickness, tensile strength, water vapor transmission rate and in vitro dissolution study. All formulations showed extended drug release over a period of 12 hours. The levels of polymer and plasticizer had a significant influence on the drug release in initial periods. Diffusion exponents of all formulations were less than 0.5, which confirmed that drug release occurred without swelling of inserts. Water vapor transmission rate was influenced by concentration of plasticizer. The best formulation showed 81.26% drug release in vivo at the end of 12 h with cellulose acetate and 79.06% with cellulose acetate butyrate. The in vitroin vivo release correlation was evaluated and the regression coefficient was found to be 0.9767 and 0.9007 for cellulose acetate and cellulose acetate butyrate formulation, respectively indicating good correlation between the in vitro and in vivo drug release.
INTRODUCTION
Ophthalmic drug delivery is one of the most interesting and challenging endeavours faced by the pharmaceutical scientist. The anatomy, physiology and biochemistry of the eye render this organ exquisitely impervious to foreign substances. The development of newer, more sensitive diagnostic techniques and therapeutic agents render urgency to the development of successful ocular drug delivery systems.
Topical delivery into the conjunctival cul-de-sac is, by far, the most common route of ocular drug delivery.
The topical application of ophthalmically active drugs to the eye is the most prescribed route of administration for the treatment of various ocular disorders. It is generally agreed that the intraocular bioavailability of topically applied drugs is extremely poor [1, 2] . The conventional ocular dosage forms pose various constraints like short residence time, large drainage factor, frequent instillation and pulsed dosing of drug. The therapeutic efficacy of drug for ophthalmic use can be greatly improved by prolonging its contact with the corneal surface. Some of the newer, sensitive and successful ocular drug delivery systems like inserts, biodegradable polymeric systems and collagen shields are being developed in order to attain ocular bioavailability and sustained action of drugs.
Ocular inserts offer an attractive alternative approach to the difficult problem of prolonging pre-corneal drug residence time by providing a controlled release of the drug. They are composed of a polymeric support containing drug(s) incorporated as dispersion or solution in the polymeric support.
Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae. It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes.
The aim of the research work was to formulate and evaluate sustained release ocular inserts using Cellulose Acetate (CA) and Cellulose Acetate Butyrate (CAB) as polymeric films in view to sustain the release of drug in the eye cavity.
MATERIALS AND METHODS

Materials
Chloramphenicol was obtained as a gift sample from Ophthal Remedies (Surendranagar, India). Cellulose acetate and cellulose acetate butyrate were procured from Rolex Chemical Industries (Mumbai, India) while glycerin and dibutyl phthalate were obtained from S. D. Fine Chemicals Ltd. (Mumbai, India).
Formulation of ocular films
Cellulose acetate and cellulose acetate butyrate were used as film forming polymers in three different concentrations with dibutyl phthalate or glycerin as plasticizers in two different concentrations.
Ocular films containing chloramphenicol were prepared by solvent casting technique using Anumbra ® petridish (Bharat Enterprises, New Delhi, India).
Cellulose acetate or cellulose acetate butyrate was dissolved in the required amount of acetone using a magnetic stirrer. The drug was dissolved separately in 2 ml acetone and added to the polymeric solution. The plasticizer was added and stirred for 10 min using magnetic stirrer. The resulting solution was poured into Anumbra ® petridish of diameter 9 cm. Evaporation of solvent was carried out in a controlled manner using an inverted funnel at room temperature for 24 h. After complete drying, the prepared films were wrapped in aluminium foil and packed in air-tight bags till further use. Ocular films of 9 mm diameter containing 1 mg chloramphenicol were cut using a cork borer at the time of use. Tables 1 and 2 outline the composition of the different formulations prepared using cellulose acetate and cellulose acetate butyrate respectively.
Evaluation of ocular films
Drug content uniformity: Ocular films of 9 mm diameter were kept in 10 ml vials and equilibrated with 5 ml isotonic sodium phosphate buffer (pH 7.4) for 24 h. The vials were shaken at various intervals during this period. Samples were withdrawn, diluted appropriately and assayed spectrophotometrically at 278 nm to determine the drug content. The readings were recorded in triplicate and the drug content expressed as mean + SD of three determinations.
Thickness: Thickness of each formulation was measured using Baker Digital Caliper (Baker Gauges India Pvt Limited, Pune, India) at five different points. Readings were recorded and mean thickness and standard deviation calculated.
Water vapor transmission study:
The studies were carried out using 10 ml vials containing 1 g of CaCl 2 . These vials were tightly covered with film formulation using an adhesive tape and kept in a desiccator maintained at 84 % r.h. using a saturated KCl solution. The vials were weighed initially before placing in the desiccator and reweighed at 24 h intervals up to 7 days. Water vapor transmission rate was calculated using equation I: In-vitro dissolution study: Ocular films of 9 mm diameter were placed in a 100 ml beaker containing 25 ml isotonic sodium phosphate buffer (pH 7.4). A wire net was placed over the film to prevent movement of the film. The beaker was placed on magnetic stirrer and the solution stirred vigorously. Samples were withdrawn after every hour for 12 hours and replaced with equal volumes of fresh buffer. The samples were analyzed for drug content against isotonic sodium phosphate buffer as a blank at wavelength of 278 nm using double beam UV visible spectrophotometer (Shimadzu 1700PC, Kyoto, Japan) .The drug release and % drug release at the end of every hour was calculated from slope of the calibration standard curve. Figures 1 and 2 are plots of % drug release against time for CA and CAB formulations, respectively.
Treatment of dissolution data with different release models
To determine the mechanism of drug release from ocular films, the dissolution data obtained from the above experiments were treated to the different release kinetic models [4, 5] according to the following equations:
Zero order kinetics:
Where Q is the amount of drug released and K 0 is zero order release rate constant.
Higuchi's square root of time model:
Where Q is the amount of drug released and K H is Higuchi release rate constant.
Korsmeyer and Peppas kinetics:
where M t is drug release at time t, M ∞ is total amount of drug in the formulation, F is fraction of drug release at time t, K m is constant dependent on geometry of dosage form and n is diffusion exponent indicating the mechanism of drug release. For films, a value of n = 0.5 indicates Fickian diffusion, n = 0.5-1.0 indicates anomalous transport and n = 1.0 indicates case-II transport.
Sterilization and test for sterility
The optimized formulations from both systems (A3 and B5) were sterilized separately in their final package container by exposing them to UV radiation at 254 nm for 90 min [6] . The irradiated ophthalmic inserts were tested for sterility according to the Indian Pharmacopoeia (IP) specifications [7] . The tests were carried out under aseptic conditions to avoid accidental contamination of the product during the test.
In vivo studies
In vivo studies were carried out after obtaining clearance from the Ethical Committee of K.L.E. Society's College of Pharmacy. Sterilized formulations A3 and B5 were selected for in vivo drug release study. Five male albino rabbits each weighing 2-2.5 kg were selected. The study was carried out by placing one insert of optimized formulation in the conjuctival cul-desac of the right eye and blank film in the conjunctival cul-de-sac of the left eye, which served as the control [8] [9] . The ocular inserts were carefully removed after 1, 2, 3, 6 and 12 h and analyzed for drug content by UV spectrophotometry at 278 nm. The drug content obtained was used to calculate the amount of drug released in the rabbit's eye. The studies were carried out in triplicate and results are expressed as mean + SD.
The in vitro data and in vivo results obtained were correlated by plotting the in vitro drug release against in vivo drug release. The regression coefficient was calculated using Microsoft Excel ® .
RESULTS AND DISCUSSION
The results of thickness, water vapour transmission, tensile strength and drug content uniformity are shown in Table 3 . The drug content range for formulations based on CA was 0.927-1.011 mg while that for CAB formulations was 0.964-1.003 mg. The standard deviation was found to be negligible thus establishing the content uniformity of the film produced. The maximum thickness observed was 0.126 mm and 0.124 mm for CA and CAB formulations, respectively, which is an acceptable limit as compared to similar products in the market. It was clearly seen that there was an increase in thickness with increase in polymer concentration of formulation. Formulations based on CA showed higher transmission rates than those based on CAB. The difference in water vapor transmission rate can be attributed to the difference in film porosity, which is known to vary depending on the type and concentration of plasticizers and film former used [10] . The results of tensile strength clearly indicate that CAB films were stronger and more flexible than CA films.
The dissolution profiles (Figures 1 and 2) show that there was retardation in drug release with increase in polymer concentration in both CA and CAB formulations. Formulation A3 exhibited a controlled drug release spread over 12 h. Formulation A5 showed highest retardation, as it released 65% of drug by the end of 12 h which was not acceptable. The increase in plasticizer concentration showed increase in drug release initially. This may suggest that increasing plasticizer concentration may cause increase in film porosity and therefore increase the drug release. Similar observations of in vitro drug release were seen with CAB formulations, where B2, B4 and B6 showed relatively higher drug release. Formulation B5 showed better drug release with only 22.44 % drug being released at the end of 1 h and 73.57 % drug being released at the end of 12 h.
The dissolution data of different formulations is shown in Table 4 . The dissolution of most formulations fitted well into the Higuchi model with regression coefficients that indicated the release of drug from the ocular films to be through a diffusion mechanism. The dissolution data were analyzed using Korsmeyer Peppas model. The values of diffusion coefficients were found to range from 0.29 to 0.45 for CA films and 0.18 to 0.47 for CAB films. Since values of diffusion exponent (n) were found to be less than 0.50, the mechanism of drug release from films was characterized as Fickian diffusion [4] . The sterile inserts of A3 and B5 complied with the test for sterility as per the IP specifications. The results of in vivo studies showed 81.26% and 79.06% drug released at the end of 12 h for CA and CAB formulations respectively ( Table  5 ). The in vitro-in vivo release correlation was carried out and the regression coefficient was found to be 0.9767 and 0.9007 for CA and CAB formulation respectively indicating good correlation between the in vitro and in vivo drug release. The stability studies indicated that there was no significant difference in drug content and percentage cumulative release initially and at the end of 6 weeks. 
CONCLUSION
From the experiment conducted, it can be concluded that CAB and CA may be used as film forming agents especially for ocular drug delivery for better and sustained drug release. Both CA and CAB films showed good drug release for up to 12 h in selected formulations of chloramphenicol. From the evaluation results and appearance of films, it was found that CAB films were more suitable for designing drug loaded ocular inserts to provide sustained release of the drug in the ocular cavity.
